血栓素生成与阿司匹林使用者的出血事件的关联
Yawen Liu1,2, Yijie Liu2,3, Feiqing Liang2,3
1School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Platelets
|March 20, 2025
概括
尿中的11-脱-TXB2 (TXB2-M) 的较低水平,一个血小板激活生物标志物,预测阿司匹林治疗冠状动脉疾病患者的出血风险增加. 这一发现有助于个性化风险管理.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 冠状动脉疾病 (CAD) 是一个主要的全球健康问题,阿司匹林是常见的治疗方法.
- 在CAD患者中长期使用阿司匹林会增加出血风险.
- 尿中的11-脱-TXB2 (TXB2-M) 表明血小板激活,但其与出血的联系尚不清楚.
研究的目的:
- 调查TXB2-M水平对接受阿司匹林的CAD患者出血事件的预测价值.
- 确定TXB2-M是否可以作为阿司匹林诱导出血风险的可靠标记.
主要方法:
- 使用多因素后勤回归分析.
- 评估TXB2-M水平作为阿司匹林治疗CAD患者出血事件的预测指标.
- 在人口群体中分析了TXB2-M的变化.
主要成果:
- 较低的TXB2-M水平与三年内出血事件的风险增加显著相关 (HR:0.46;95%CI:0.26-0.79;P <0.05).
- 在TXB2-M水平上观察到的人口变化.
- 证明了TXB2-M对出血风险的预测能力.
结论:
- TXB2-M是一种有效的生物标志物,用于识别患有阿司匹林出血风险较高的CAD患者.
- 研究结果支持个性化治疗策略,以平衡抗血栓性疗效和出血风险.
- 在心血管疾病管理中,TXB2-M可以帮助优化阿司匹林治疗.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
441
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
441
01:24Disorders of Hemostasis
673
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
673
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
01:22Formation of the Platelet Plug
3.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
4.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K